	US 12,351,619 B2
	Serum albumin-binding fibronectin type III domains and uses thereof
Karyn O'Neil, Philadelphia, PA (US); Yao Xin, Philadelphia, PA (US); and Russell C. Addis, Philadelphia, PA (US)
Assigned to ARO Biotherapeutics Company, Philadelphia, PA (US)
Appl. No. 17/786,786
Filed by ARO BIOTHERAPEUTICS COMPANY, Philadelphia, PA (US)
PCT Filed Dec. 18, 2020, PCT No. PCT/US2020/065878 § 371(c)(1), (2) Date Jun. 17, 2022, PCT Pub. No. WO2021/127353, PCT Pub. Date Jun. 24, 2021.
Claims priority of provisional application 62/949,856, filed on Dec. 18, 2019.
Prior Publication US 2023/0039851 A1, Feb. 9, 2023
Int. Cl. C07K 14/765 (2006.01); C07K 14/78 (2006.01); C12N 15/63 (2006.01); G01N 33/49 (2006.01)

CPC C07K 14/765 (2013.01) [C07K 14/78 (2013.01); C12N 15/63 (2013.01); G01N 33/49 (2013.01); C07K 2319/21 (2013.01); C07K 2319/55 (2013.01); C07K 2319/70 (2013.01)]

38 Claims

1. A protein comprising an amino acid sequence that is at least 85% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.